- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02346032
Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma
Study Overview
Detailed Description
Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule.
Self-administration of refametinib tablets will take place on an outpatient basis. Patients experiencing dose-limiting toxicity attributed to study medication should have at least 1-week treatment breaks inserted into the continuous daily dosing period as needed and/or may be interrupted or reduced depending on individual tolerability.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age ≥ 18
- histologically or cytologically confirmed adenocarcinoma of biliary tract
- unresectable or metastatic
- ECOG performance status of 0~2
- measurable lesion per RECIST 1.1 criteria
- adequate marrow, hepatic, renal functions
- normal range of cardiac function confirmed by echocardiogram within 1 year (LVEF ≥50)
- Child-Pugh Class A in case of liver cirrhosis
- One prior treatment of cytotoxic chemotherapy (including adjuvant treatment within 12 months)
- Resolution of all acute toxic effects of any prior therapy to Common Toxicity Criteria for Adverse Events (CTCAE 4.03) ≤ grade 1.
- provision of a signed written informed consent
Exclusion Criteria:
- History of cardiac disease
- Ongoing infection > Grade 2 according to NCI-CTCAE version 4.03. Hepatitis B is allowed if no active replication (defined as abnormal ALT >2xULN associated with HBV DNA >20,000 IU/mL) is present
- Severe co-morbid illness and/or active infections including active hepatitis C and human immunodeficiency virus (HIV) infection
- History of interstitial lung disease (ILD).
- Any cancer curatively treated < 3 years prior to study entry, except cervical carcinoma in situ, treated basal cell carcinoma, and superficial bladder tumors (Staging: Ta, Tis and T1).
- Renal failure requiring hemo- or peritoneal dialysis.
- Clinically significant GI bleeding (CTCAE 4.03 grade 3 or higher) within 30 days prior to start of screening
- Thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks) within 6 months prior to start of screening.
- History of organ allograft, cornea transplantation will be allowed
- Active CNS metastases not controllable with radiotherapy or corticosteroids
- Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk factor for RVO or CSR.
- Known history of hypersensitivity to study drugs
- Any condition that was unstable or which could jeopardize the safety of the patient and his/her compliance in the study
- Non-healing wound, ulcer, or bone fracture.
- Patients with seizure disorder requiring medication.
- Use of strong inhibitors of CYP3A4 and strong inducers of CYP3A4 should be stopped 2 weeks before start of screening (see Appendix 1).
- Acute steroid therapy or taper for any purpose (chronic steroid therapy is acceptable provided that the dose is stable for 1 month before start of screening and thereafter).
- Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results.
- Pregnant or lactating women. Women of childbearing potential not employing adequate contraception. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to start of study treatment and a negative result must be documented before first dose of study drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: refametinib
refametinib medication
|
Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate
Time Frame: 12months
|
the rate of complete response and partial response among all evaluable patients
|
12months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
adverse events in each cycle were documented based on CTCAE v 4.03
Time Frame: 24months
|
24months
|
|
Duration of response
Time Frame: 12months
|
median time from response to progression
|
12months
|
Progression-free survival
Time Frame: 6months
|
6months
|
|
Exploratory correlative analysis
Time Frame: 15 days
|
KRAS/PIK3CA mutation testing using BEAMing assay will be planned
|
15 days
|
Overall survival
Time Frame: 12months
|
12months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014-07-148
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biliary Tract Cancer
-
Sun Yat-sen UniversityJiangsu Hengrui Pharmaceutical Co., Ltd.Not yet recruitingMetastatic Biliary Tract Cancer | Locally Advanced Biliary Tract CancerChina
-
Gyeongsang National University HospitalSamsung Medical Center; Dong-A University; Chung-Ang UniversityTerminatedMetastatic Biliary Tract Cancer | Locally Advanced Biliary Tract CancerKorea, Republic of
-
Hospital de Cancer de Barretos - Fundacao Pio XIIUnknown
-
Fudan UniversityRecruitingAdvanced Biliary Tract CancerChina
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingAdvanced Biliary Tract CancerChina
-
Tianjin Medical University Cancer Institute and...RecruitingResectable Biliary Tract CancerChina
-
University of Kansas Medical CenterRecruitingAdvanced Biliary Tract CancerUnited States
-
Peking Union Medical College HospitalShanghai Junshi Bioscience Co., Ltd.RecruitingAdvanced Biliary Tract CancerChina
-
Georgetown UniversityIpsenRecruitingAdvanced Biliary Tract CancerUnited States
-
Seoul National University HospitalBeiGeneActive, not recruitingAdvanced Biliary Tract CancerKorea, Republic of
Clinical Trials on refametinib
-
BayerTerminated
-
BayerCompletedCarcinoma, HepatocellularBelgium, France, Switzerland, Germany, United States, Austria, New Zealand, Hungary, Korea, Republic of, Italy, Hong Kong, Thailand, Spain, Taiwan, Japan, Czechia, United Kingdom
-
BayerCompletedNeoplasmsUnited States, Germany, Netherlands
-
BayerCompleted
-
BayerCompletedCarcinoma, HepatocellularBelgium, China, Hong Kong, Switzerland, Japan, France, Spain, Germany, United States, Austria, Czechia, United Kingdom, Korea, Republic of, Thailand, New Zealand, Hungary, Israel, Italy, Taiwan, Singapore, Turkey
-
BayerCompleted
-
Ain Shams UniversityUnknown